OVERVIEW
- Fecal microbiota transplantation (FMT) is recommended for recurrent Clostridioides difficile infection (CDI), but its role in primary CDI is unclear.
- The study compared FMT without antibiotic pretreatment versus oral vancomycin, 125 mg 4 times daily for 10 days
- FMT may be considered as first-line therapy in primary CDI.
STUDY DETAILS
The COLONIZE trial is a randomized, open-label, noninferiority, multicenter trial carried out in hospitals and primary care facilities in Norway.
TITLE OF PUBLICATION
Fecal Microbiota Transplantation Versus Vancomycin for Primary
Clostridioides difficile Infection
AUTHORS
Frederik Emil Juul, MD, PhD; Michael Bretthauer, MD, PhD; Peter H. Johnsen, MD, PhD; Faye Samy, BSc; Kristian Tonby, MD, PhD; Jan Erik Berdal, MD, PhD; Dag Arne L. Hoff, MD, PhD; Eirik H. Ofstad, MD, PhD; Awet Abraham, MD; Birgitte Seip, MD, PhD; Håvard Wiig, MD; Øyvind Bakken Rognstad, MD; Ida F. Glad, MD; Jørgen Valeur, MD, PhD; Axel E. Nissen-Lie, MD; Eivind Ness-Jensen, MD, PhD; Kristine M.A. Lund, MD; Linn K. Skjevling, MD; Kurt Hanevik, MD, PhD; Hilde Skudal, MD; Ellen J. Melsom, MD; Raziye Boyar, MD, PhD; Trond J. Cooper, MD; Trond E. Ranheim, MD; Esben M. Riise, MD; Hans-Olov Adami, MD, PhD; Mette Kalager, MD, PhD; Magnus Løberg, MD, PhD; and Kjetil K. Garborg, MD, PhD
Publication Reference
Annals of Internal Medicine | Volume 178 (7)| 940-947| Publication Year 2025
